Sacubitril/Valsartan and Heart Failure: Improvement of Health Status

Sacubitril/Valsartan and Heart Failure: Improvement of Health Status Posted By:
...

For the last few years, we have seen a number of continuing education sessions and articles related to advances in the treatment of heart failure (HF). One of the newer medications, sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been added as a preferred agent for treatment of HF with reduced ejection fraction (HFrEF) in the 2021 Update to the American College of Cardiology (ACC) consensus algorithm.

A recent article in JACC Heart Failure highlighted promising news about improvement in health status for patients who initiated on sacubitril/valsartan. The study, which took place over 12 months, evaluated changes from baseline in both Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 responses and amino-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The results showed that patients who were started on sacubitril/valsartan had a rapid improvement in KCCQ-23 scores that was significantly related to changes in their NT-proBNP levels.

This is promising news for our patients with HFrEF. Using sacubitril/valsartan appropriately in HFrEF can help patients feel better earlier—consequently allowing for greater quality of life and increasing the odds that they will adhere to the treatment regimen.

References
  • Maddox TM, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. JACC. 2021;77:772.
  • Pina IL, et al. Improvement of health status following initiation of sacubitril/valsartan in heart failure and reduced ejection fraction. JACC Heart Fail. 2021;9:42.

Share

Filed under: Cardiometabolic

Related
Phase III FLOW Trial Results Establishes Semaglutide’s Role in Treating T2D and CKD

Phase III FLOW Trial Results Establishes Semagluti ...

The highly anticipated results of the FLOW (Evaluate Renal Function with Semaglutide Once Weekly) tr ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
The Gift of Time and Key Connection Between Diabetes Mellitus and Autoimmune Disorders

The Gift of Time and Key Connection Between Diabet ...

Are you aware that approximately 64,000 Americans are diagnosed with type 1 diabetes (T1D) each year ...

Filed under: Cardiometabolic


Continue Reading
The Importance of Shared Decision-making in Obesity

The Importance of Shared Decision-making in Obesit ...

Many areas of healthcare are starting to talk about the importance of shared decision-making (SDM), ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Addressing ASCVD Risk in HIV: An Update to the DHHS HIV Guidelines

Addressing ASCVD Risk in HIV: An Update to the DHH ...

The incidence of atherosclerotic cardiovascular disease (ASCVD) is estimated to be twice as high in ...

Filed under: Infectious Diseases, Preventive Medicine, Public Health, Cardiometabolic, NPs & PAs


Continue Reading
Understanding the Multifactorial Etiology of Obesity and the Metabolic Adaptations to Weight Loss

Understanding the Multifactorial Etiology of Obesi ...

Obesity Causes Overeating, Not the Other Way AroundOne of my favorite quotes from Dr Lee Kaplan is, ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading
Atrial Fibrillation: Optimizing Outcomes by Addressing Social Determinants of Health and Implicit Bias

Atrial Fibrillation: Optimizing Outcomes by Addres ...

Atrial fibrillation (AF) is the most common sustained arrhythmia diagnosed, and its prevalence is ex ...

Filed under: Cardiometabolic, NPs & PAs


Continue Reading